CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 32 enrolled
Drug / intervention
Substance P +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04676763
NCT04676763N/ACompleted
CompareCT.gov

An Open Label, Single Centre, Enabling Study to Investigate the Optimum Method for Use of Intradermal Substance P as a Challenge Agent in Healthy Participants

GlaxoSmithKline·interventional·Posted Dec 21, 2020·Updated Jan 20, 2025

In Brief

A clinical study evaluating Substance P, Normal Saline, and 1 other intervention for Skin Diseases. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The objectives of this enabling study are to characterize the wheal and flare responses over time following skin challenges with ascending concentrations of Substance P. This will be a 2-part study: Part 1 will aid in the understanding of the wheal and flare responses following Substance P. Part 2 will investigate the variability of the responses. Participants may be enrolled into Part 1 or Part 2, not both.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Diseases
CountriesNetherlands
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedDec 21, 2020
Enrollment StartMar 2, 2021
Primary CompletionJul 21, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.5 years ago

Interventions

Substance Pdrug

Participants will receive Substance P

Normal Salinedrug

Participants will receive normal saline as Negative control

Histaminedrug

Participants will receive histamine as Positive control